Actuate Therapeutics (ACTU) announced new positive data from its ongoing and fully enrolled randomized Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel in first line treatment of metastatic pancreatic ductal adenocarcinoma, mPDAC. A pre-specified analysis was triggered by reaching greater than70% death events in the GnP control arm. The analysis of interim data demonstrated treatment with elraglusib in combination with GnP resulted in statistically significant increases in 1-year survival rate (p value of 0.002) and median overall survival versus treatment with GnP alone. The combination treatment also resulted in increased Objective Response Rates and Disease Control Rates in the elraglusib/GnP combination arm versus the GnP control arm.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACTU:
- Actuate Therapeutics added to Russell 2000 Index
- Actuate announces FDA rare pediatric disease designation to elraglusib
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
